(Photo Courtesy: www.sbhyd.com)
"I am very excited to be working Mitra Biotech. I am impressed with the extensive clinical validation of CANScript, and believe that it will be a highly-useful tool for cancer patients as well for companies developing oncology therapeutics," said Dr Eric.
Dr Eric Rowinsky was previously the chief medical officer for ImClone Systems.
He is currently the chief medical officer and head of research and development of Stemline Therapeutics.
He also currently serves on the board of directors of Biogen Idec, as well as several other public biopharmaceutical companies. He is also Editor-in-Chief of Investigational New Drugs (The Journal of New Anticancer Agents).
"We are honored to work with Dr Rowinsky," said Dr Mallik Sundaram, CEO of Mitra. "Dr Rowinsky's extensive knowledge of oncology drugs and personalized medicine, as well as his broad expertise with cancer clinical trials, will certainly prove valuable to Mitra as we continue to develop and grow CANScript platform in the theranostics and drug development arenas. We are particularly pleased at the timing as Mitra is in discussions with USFDA with regards to pivotal clinical trials leading to commercialization of CANScript in the US market."
